Elbasvir/Grazoprevir (Zepatier®)

Assessment Status Rapid review complete
Drug Elbasvir 50mg/100mg grazoprevir
Brand Zepatier®
Indication For the treatment of genotypes 1 and 4 chronic HCV infection in patients with Child-Turcotte-Pugh score A (CTPA)
Assessment Process
Rapid review commissioned 10/08/2016
Rapid review completed 13/10/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended for (EBR/GZR)